KTTA.US Pasithea Therapeutics Corp

Healthcare Biotechnology USA Stocks
0.5220 USD
Close of Nov 15, 2026
0.2810 2.06
Market cap
USD 17.4M
P/E
-
P/B
0.35x
ROE
-20.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KTTA.US undervalued?

Graham number

The Graham number of Pasithea Therapeutics Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pasithea Therapeutics Corp fundamental analysis

No fundamental analysis for Pasithea Therapeutics Corp yet.

Pasithea Therapeutics Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pasithea Therapeutics Corp

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 dr…

Full company profile